Advertisement


Clifford A. Hudis, MD: A Message From ASCO’s CEO

2024 ASCO Annual Meeting

Advertisement

Clifford A. Hudis, MD, of the American Society of Clinical Oncology (ASCO), talks about the 2024 Annual Meeting, and a focus on the compassionate side of cancer care.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Welcome, everybody, to the 60th Annual ASCO Meeting. This meeting is an especially meaningful and exciting one for me because this comes on the heels of decades of really powerful advances across all of oncology, including, of course, targeted therapy, small molecules, immunotherapy, and engineered cells, among many other advances that I'd say in the last five to 10 years have truly transformed oncology. But what makes this year's meetings especially exciting, is that we have coupled this with a call for humanism in medicine and a reminder of the privilege of caring for patients and families through this most difficult time. Our president, Dr. Lynn Schuchter, who's been on the leading edge of the most exciting advances in cancer, especially those in melanoma, at the same time is one of the most compassionate, holistic kinds of physicians anyone could hope to see, and she brings that with passion to this meeting. So we're very, very excited by the inclusion of so many new resources and learnings for our community to help them help their patients around the world more effectively than ever before.

Related Videos

Prostate Cancer
Genomics/Genetics

Alicia Morgans, MD, MPH, and Susan Halabi, PhD, on Prostate Cancer: New Findings on Classifying Patients Into Risk Groups

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).

Gynecologic Cancers

Don S. Dizon, MD, on Ovarian and Other Extrarenal Clear Cell Carcinomas: Update on Nivolumab and Ipilimumab

Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).

Bladder Cancer

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: The DESTINY-Pan Tumor02 Study and New Findings on Sacituzumab Govitecan

Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss clinical outcomes of sacituzumab govitecan-hziy after prior exposure to enfortumab vedotin-ejfv in patients with metastatic urothelial carcinoma, as well as the safety and efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-expressing bladder tumors (Abstracts 4502 and 4509).

Multiple Myeloma

Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.

Breast Cancer

Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who received sacituzumab govitecan-hziy with or without pembrolizumab (LBA1004).

Advertisement

Advertisement




Advertisement